HomeCONGRESS

CONGRESS

View Category
Day 2

VISTA 16: anti-inflammatory agent in acute coronary syndromes

There is evidence that inflammation would have an impact on the prognosis of patients experiencing acute coronary...
solaci -
Learn More
Day 2

TOPCAT: Spironolactone in heart failure with preserved ejection fraction

The aldosterone blockade has shown benefit in the treatment of heart failure with systolic dysfunction after stroke....
solaci -
Learn More
Day 2

Plastic versus mitral valve replacement in ischemic mitral regurgitation

Unlike degenerative mitral insufficiency, ischemic failure is due to an increase in the left ventricular cavity, the...
solaci -
Learn More
Day 3

ERASE: Endovascular treatment plus exercise versus exercise alone to treat claudication

Initial therapy for intermittent claudication has been historically the gear train, however, especially in recent years; the...
solaci -
Learn More
Day 3

RADAR AF: High-frequency ablation versus pulmonary vein isolation to treat atrial fibrillation

Atrial fibrillation is initiated by focal triggers and maintained by an atrial substrate called fractioned complex of...
solaci -
Learn More
Day 3

EU-PACT: Warfarin dose guided by genotype

Anticoagulation level in response to a fixed dose of warfarin is difficult to predict at the start...
solaci -
Learn More
Day 3

ENGAGE AF-TIMI 48: Endoxaban versus warfarin in atrial fibrillation

The endoxaban is an oral direct inhibitor of factor Xa with a rapid onset of action and...
solaci -
Learn More
Day 3

STREAM Trial: Pharmacological-invasive strategy versus primary angioplasty

The STREAM study (Strategic Reperfusion Early After Myocardial Infarction) that included 1891 patients gave support to the...
solaci -
Learn More